Immunology patent intelligence

US 9061016

Aqueous solution comprising 3-quinuclidinones for the treatment hyperproliferative, autoimmune and heart disease

APREA AB · Granted Tue Jun 23 2015 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 18 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

US 9023984

Diagnostic and therapeutic target for autoimmune diseases and uses thereof

The Regents of the University of Colorado, a Body Corporate · Granted Tue May 05 2015 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 30 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

US 9017644

Methods of treating autoimmune disorders and/or inflammatory disorders

THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted Tue Apr 28 2015 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 23 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

US 8987228

Pharmaceutical composition including an A3 adenosine receptor agonist 1-deooxy-1-[N6-(3-idobenzyl)-adenin-9-yl]-N-methyl-β-D-ribofuronamide(IB-MECA/CF-101) for treatment of psoriasis

CAN-FITE BIOPHARMA LTD. · Granted Tue Mar 24 2015 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 19 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

US 8895539

Pregnancy hormone combination for treatment of autoimmune diseases

The Regents of the University of California · Granted Tue Nov 25 2014 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 20 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

US 8889661

Treatment of lupus nephritis using laquinimod

TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Tue Nov 18 2014 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 13 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

US 8835405

Inhibiting arthritis via injection of synergistic combination of hyaluronic acid and vitamin C and/or vitamin E

China Medical University · Granted Tue Sep 16 2014 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 11 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

US 8821866

Methods of treating and preventing colitis involving IL-13 and NK-T cells

The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Sep 02 2014 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 28 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

US 8795656

Methods of treating rheumatoid arthritis by administering an anti-IL3 antibody

Klinikum der Universität Regensburg · Granted Tue Aug 05 2014 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 31 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

US 8765125

Methods of treating autoimmune diseases with Dll4 antagonists

REGENERON PHARMACEUTICALS, INC. · Granted Tue Jul 01 2014 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 26 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

US 8759302

Methods of treating a subject afflicted with an autoimmune disease using predictive biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis

TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Tue Jun 24 2014 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 19 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

US 8729039

Use of inhibitory oligonucleotides to treat autoimmune disease

The Regents of the University of California · Granted Tue May 20 2014 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 15 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

US 8712696

Methods of prognosing a rheumatoid arthritis remission phenotype

PROGENIKA BIOPHARMA, S.A. · Granted Tue Apr 29 2014 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 24 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

US 8680066

Methods for determining and inhibiting rheumatoid arthritis associated with the BRAF oncogene in a subject

The United States of America as represented by the Development of Veterans Affairs · Granted Tue Mar 25 2014 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 20 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

US 8673300

Therapeutic compositions and methods for the prevention of autoimmune diseases

The Regents of the University of Colorado, a Body Corporate · Granted Tue Mar 18 2014 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 13 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

US 8658627

Pregnancy hormone combination for treatment of autoimmune diseases

The Regents of the University of California · Granted Tue Feb 25 2014 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 20 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

US 8637031

Method of treating osteoarthritis with an antibody to NGF

REGENERON PHARMACEUTICALS, INC. · Granted Tue Jan 28 2014 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 23 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

US 8598203

Treatment of Crohn's disease with laquinimod

TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Tue Dec 03 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 28 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

US 8592456

IL17 and IFN-gamma inhibition for the treatment of autoimmune inflammation

4SC DISCOVERY GMBH · Granted Tue Nov 26 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 21 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

US 8568721

Method of treating rheumatoid arthritis with an anti-IL-6R antibody

REGENERON PHARMACEUTICALS, INC. · Granted Tue Oct 29 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 24 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

US 8557806

Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds

Rigel Pharmaceuticals, Inc. · Granted Tue Oct 15 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 10 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

US 8529885

AAV vectors for in vivo gene therapy of rheumatoid arthritis

ACADEMISCH MEDISCH CENTRUM · Granted Tue Sep 10 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 05 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

US 8501705

Methods and materials for treating autoimmune and/or complement mediated diseases and conditions

The Board of Regents of the University of Texas System · Granted Tue Aug 06 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 01 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

US 8501766

Treatment of rheumatoid arthritis with a combination of laquinimod and methotrexate

TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Tue Aug 06 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 01 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

US 8497279

Treatment for discoid lupus

Rigel Pharmaceuticals, Inc. · Granted Tue Jul 30 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 25 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

US 8492347

Peptide for induction of immune tolerance as treatment for systemic lupus erythematosus

The Regents of the University of California · Granted Tue Jul 23 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 18 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

US 8455553

Methods and compositions for prevention and treatment of inflammatory disease, autoimmune disease and transplant rejection

The Regents of the University of California · Granted Tue Jun 04 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 30 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

US 8404732

Methods of treating ulcerative colitis

LEXICON PHARMACEUTICALS, INC. · Granted Tue Mar 26 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 21 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

US 8377444

Therapeutic agent or preventive agent for osteoarthritis

AXIS · Granted Tue Feb 19 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 14 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

US 8372826

Estriol therapy for multiple sclerosis and other autoimmune diseases

The Regents of the University of California · Granted Tue Feb 12 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 07 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

US 8354436

IL17 and IFN-gamma inhibition for the treatment of autoimmune inflammation

4SC DISCOVERY GMBH · Granted Tue Jan 15 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 10 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

US 8323617

Treatment of arthritis and other musculoskeletal disorders with crosslinked hyaluronic acid

ANIKA THERAPEUTICS, INC. · Granted Tue Dec 04 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 29 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

US 8324165

Compositions for treating arthritis comprising HG1023575 polypeptide

Five Prime Therapeutics, Inc. · Granted Tue Dec 04 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 29 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

US 8314093

2,4-pyrimidinediamine compounds for treating or preventing autoimmune diseases

Rigel Pharmaceuticals, Inc. · Granted Tue Nov 20 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 15 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

US 8309088

Method of treating osteoarthritis with an antibody to NGF

REGENERON PHARMACEUTICALS, INC. · Granted Tue Nov 13 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 08 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

US 8192741

Method of treating rheumatoid arthritis with an anti-IL-6R antibody

REGENERON PHARMACEUTICALS, INC. · Granted Tue Jun 05 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 31 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

US 8178671

Methods of treating or preventing autoimmune diseases with 2, 4-pyrimidinediamine compounds

Rigel Pharmaceuticals, Inc. · Granted Tue May 15 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 10 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

US 8173123

Methods of treating colitis involving IL-13 and NK-T cells

The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue May 08 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 03 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

US 8158621

Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds

Rigel Pharmaceuticals, Inc. · Granted Tue Apr 17 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 12 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

US 8101174

Pharmaceutical compositions for treating arthritis and inflammatory disease

The Regents of the University of California · Granted Tue Jan 24 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 19 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

US 8093267

Methods of treating rheumatoid arthritis

LEXICON PHARMACEUTICALS, INC. · Granted Tue Jan 10 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 05 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

US 8080527

Methods and compositions for prevention and treatment of inflammatory disease, autoimmune disease, and transplant rejection

The Regents of the University of California · Granted Tue Dec 20 2011 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 15 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

US 8080248

Method of treating rheumatoid arthritis with an IL-6R antibody

REGENERON PHARMACEUTICALS, INC. · Granted Tue Dec 20 2011 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 15 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

US 8052970

Lysosomal phospholipase A2 (LPLA2) activity as a diagnostic and therapeutic target for identifying and treating systemic lupus erythematosis

THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted Tue Nov 08 2011 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 03 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

US 7993866

Diagnosis, prevention and treatment of crohn's disease using the OmpC antigen

The Regents of the University of California · Granted Tue Aug 09 2011 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 04 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

US 7993867

Diagnosis, prevention and treatment of crohn's disease using the OmpC antigen

The Regents of the University of California · Granted Tue Aug 09 2011 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 04 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

US 7993865

Diagnosis, prevention and treatment of Crohn's disease using the OmpC antigen

The Regents of the University of California · Granted Tue Aug 09 2011 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 04 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

US 7923010

Methods and materials for treating autoimmune diseases and conditions

The Board of Regents of the University of Texas System · Granted Tue Apr 12 2011 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 07 2031 00:00:00 GMT+0000 (Coordinated Universal Time)